Tecomet and Orchid complete merger to form global medical manufacturing platform

Tecomet and Orchid Orthopedic Solutions have closed their merger, creating a scaled global contract manufacturing platform serving MedTech and aerospace & defense customers. The combined entity operates under the Tecomet name, with Andreas Weller continuing as CEO. The company now spans 24 manufacturing sites across the U.S., U.K., Switzerland, and additional countries, integrating capabilities in precision machining, forging, casting, additive manufacturing, photochemical etching, bone in-growth coatings, advanced finishing, and sterile packaging. The merger combines Tecomet’s 14 facilities with Orchid’s 10 facilities, with Orchid’s specialization in implants and instruments for joint reconstruction, hips, knees, spine, trauma, extremities, and dental applications.

This merger consolidates two of the largest independent medical device contract manufacturers, directly addressing OEM demand for supply resilience and single-partner scale across the product lifecycle. In the context of the broader AM industry, the deal underscores how additive manufacturing is being embedded as a complementary capability within traditional precision manufacturing platforms rather than standing alone. Tecomet and Orchid both operate metal AM (LPBF and binder jetting) for orthopedic implants and instruments, but the merger’s significance lies in the combined forging, casting, and machining capacity that gives OEMs a single source for high-volume legacy production alongside AM-enabled design iteration. This mirrors the pattern seen in aerospace, where AM succeeds by disappearing into larger manufacturing workflows. The combined entity now competes directly with other large-scale MedTech contract manufacturers like Cretex, Integer, and Jabil Healthcare, but with a notably broader technology stack.

For Tecomet, the immediate execution priority is phased integration across 24 sites without disrupting existing customer qualification and regulatory filings. The combined company’s ability to offer AM alongside traditional forging and casting will be tested by whether OEMs actually consolidate supplier portfolios or continue splitting work across multiple specialists. The real value will depend on how effectively the integration teams align quality systems and regulatory documentation across sites, not on the scale of the combined facility count alone.